Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Exact Sciences Corp (NASDAQ: EXAS) closed at $44.99 up 0.18% from its previous closing price of $44.91. In other words, the price has increased by $0.18 from its previous closing price. On the day, 4.09 million shares were traded. EXAS stock price reached its highest trading level at $45.075 during the session, while it also had its lowest trading level at $43.665.
Ratios:
For a deeper understanding of Exact Sciences Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.92 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 50.21. For the most recent quarter (mrq), Quick Ratio is recorded 2.56 and its Current Ratio is at 2.89. In the meantime, Its Debt-to-Equity ratio is 1.03 whereas as Long-Term Debt/Eq ratio is at 1.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $60.
On March 13, 2025, RBC Capital Mkts started tracking the stock assigning a Sector Perform rating and target price of $52.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $70.Barclays initiated its Overweight rating on January 23, 2025, with a $70 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 13 ’25 when Doyle James Edward sold 1,485 shares for $42.02 per share. The transaction valued at 62,400 led to the insider holds 59,962 shares of the business.
Doyle James Edward bought 1,485 shares of EXAS for $62,400 on Aug 13 ’25. On Jul 16 ’25, another insider, Sebelius Kathleen, who serves as the Former Director of the company, bought 8,164 shares for $53.11 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 8517462528 and an Enterprise Value of 10180743168. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.90 while its Price-to-Book (P/B) ratio in mrq is 3.45. Its current Enterprise Value per Revenue stands at 3.463 whereas that against EBITDA is 130.052.
Stock Price History:
The Beta on a monthly basis for EXAS is 1.05, which has changed by -0.23421276 over the last 52 weeks, in comparison to a change of 0.16461086 over the same period for the S&P500. Over the past 52 weeks, EXAS has reached a high of $72.83, while it has fallen to a 52-week low of $38.81. The 50-Day Moving Average of the stock is -11.25%, while the 200-Day Moving Average is calculated to be -14.24%.
Shares Statistics:
For the past three months, EXAS has traded an average of 3.21M shares per day and 5349890 over the past ten days. A total of 189.22M shares are outstanding, with a floating share count of 186.86M. Insiders hold about 1.30% of the company’s shares, while institutions hold 97.59% stake in the company. Shares short for EXAS as of 1753920000 were 6875496 with a Short Ratio of 2.14, compared to 1751241600 on 7015295. Therefore, it implies a Short% of Shares Outstanding of 6875496 and a Short% of Float of 4.1500002.
